A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of...

Full description

Saved in:
Bibliographic Details
Published in:J Cereb Blood Flow Metab
Main Authors: Varrone, Andrea, Varnäs, Katarina, Jucaite, Aurelija, Cselényi, Zsolt, Johnström, Peter, Schou, Magnus, Vazquez-Romero, Ana, Moein, Mohammad M, Halldin, Christer, Brown, Andrew P, Vishwanathan, Karthick, Farde, Lars
Format: Artigo
Language:Inglês
Published: SAGE Publications 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7168784/
https://ncbi.nlm.nih.gov/pubmed/31006308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0271678X19843776
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items